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Abstract 
Purpose: Mutations in the genes coding for subunits of ion channels have been associated 
with epilepsy. Of these known epilepsy genes SCN1A, coding for the α subunit of the 
sodium channel, is currently the most clinically relevant gene. The majority of SCN1A 
mutations lead to severe myoclonic epilepsy of infancy (SMEI) including borderline SMEI 
(SMEB) and to generalized epilepsy with febrile seizures plus (GEFS+). Both syndromes 
have febrile seizures (FS) as a common clinical feature. The aim of this study was to 
achieve a better definition of the spectrum of phenotypes that might be associated with 
SCN1A mutations. We aimed to performing phenotype-genotype correlations of SCN1A 
mutations with specific epilepsy syndromes.  
Methods: We selected 132 patients in whom most seizures occurred during febrile 
episodes. A clinical and genetic study focussing on SCN1A screening was performed.  
Results: Patients were classified as follow: SMEI/ SMEB = 55; GEFS+ spectrum= 25; 
sporadic myoclonic astatic epilepsy= 3; classical FS= 10; other phenotypes= 25. We 
identified 40 SCN1A mutations. Of the 40 mutations 37 were found in patients with SMEI 
in whom mutations were missense in 16 probands (2 familial) and truncating in 21 (2 
familial). The remaining 3 missense mutations were associated with GEFS+. Missense 
mutations in the pore forming parts (S5-S6) of the Na+ channel occurred in 10 out of the 16 
SMEI (62,5%) and only in one of the three GEFS+ patients. Mutations in the pore forming 
region seem to correlate in 70% with the classical SMEI type and only with 30% of the 
SMEB phenotype. Analysis of the age of seizures onset between SMEI patients with: a) 
SCN1A truncating mutations, b) SCN1A missense mutations and c) no SCN1A mutations 
showed that the differences of the age of FS onset was extremely significant between the 
three groups (p=0,0007, ANOVA test). Patients with truncating mutations had the earlier 
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onset of FS, patients with missense mutations had an intermediate onset, and individuals 
without SCN1A mutations had the latest age of FS onset.  
Conclusion: We obtained a prevalence of about 70% of SCN1A mutations in SMEI and 
SMEB patients and of 12% in GEFS+ probands confirming the predominant and important 
role of SCN1A in patients with SMEI. None of the other patients with fever-provoked 
seizures carried mutations in SCN1A gene. The high correlation between SMEI and SCN1A 
mutations suggests a phenotypical specificity of SCN1A rather than a dysfunction of 
neurons exacerbated by high body temperature 
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Introduction 
Voltage-gated sodium channels are essential for the generation and propagation of 
action potentials in the brain as well as in other excitable tissues. Mutations in the genes 
coding for the α1 and β1subunits of the neuronal sodium channel (SCN1A and SCN1B 
respectively) have been associated with epilepsy. The overwhelming majority of SCN1A 
known mutations lead to severe myoclonic epilepsy of infancy (SMEI) and to generalized 
epilepsy with febrile seizures plus (GEFS+) (Mulley et al., 2005). 
GEFS+ is a complex and heterogeneous familial syndrome with autosomal 
dominant inheritance in some families in which febrile seizures (FS) and febrile seizures 
plus (FS+) are the predominant phenotypes (Scheffer and Berkovic, 1997; Singh et al., 
1999a). SCN1A and SCN1B mutations have been found in about 10% of GEFS+ families 
(Bonanni et al., 2004; Escayg et al., 2001; Escayg et al., 2000; Scheffer et al., 2000; 
Wallace et al., 2001; Wallace et al., 2002; Wallace et al., 1998). 
Severe myoclonic epilepsy of infancy (SMEI) or Dravet’s Syndrome is an epileptic 
encephalopathy presenting with prolonged febrile or afebrile generalized or unilateral 
clonic seizures in the first year of life in an otherwise normal infant (Dravet, 2002). 
Between 1 to 4 years other seizure types occur including myoclonic, absences and partial 
seizures, developmental delay becomes also apparent within the second year of life. Several 
authors described group of patients sharing most but not all the characteristic clinical 
features of SMEI patients and designated them as ‘borderline SMEI (SMEB)’ (Fukuma et 
al., 2004; Oguni et al., 2001). A family history of epilepsy is often found in SMEI patients 
and affected relatives have epilepsy phenotypes consistent with GEFS+ (Scheffer and 
Berkovic, 1997; Singh et al., 1999a; Singh et al., 1999b). Mutations of SCN1A have been 
found in 40 to 100% of SMEI patients and are de novo in the majority of individuals (Claes 
et al., 2001; Nabbout et al., 2003; Sugawara et al., 2002; Wallace et al., 2003).  
SCN1A: phenotype-genotype correlations  5 
Clinical analysis of the phenotypes shows clearly that the first clinical sing of 
mutations in SCN1A is recurrent, often prolonged, seizures provoked by fever in infancy. 
This evidence suggests that, in clinical practice, mutations in SCN1A could be suspected in 
every child with fever-provoked seizures. Febrile seizures are the most common convulsive 
event in humans and about 13% of patients with epilepsy have a history of FS (Frucht et al., 
2000). The largest percentage of FS (25%) is observed in temporal lobe epilepsy, often 
characterized by the sequence of prolonged FS in childhood, hippocampal sclerosis (HS) 
and refractory temporal lobe seizures (Baulac et al., 2004). Sporadic patients with TLE and 
HS have been described in GEFS+ families with SCN1A and SCN1B mutations (Abou-
Khalil et al., 2001; Wallace et al., 2002). These data, thus confirm the role of sodium 
channel genes in decreasing seizures threshold causing fever-provoked seizures in infancy 
and more specific seizure types later in the course of the syndrome. Modifier genes and 
environmental factors might be also involved to determine the phenotype specificity and 
the epilepsy outcome.  
Following these considerations, we performed a clinical and genetic study focussing 
on SCN1A screening of a large series of patients with various epilepsy phenotypes whose 
common clinical feature was represented by the occurrence of fever-provoked seizures. The 
present study aimed to achieve a better definition of the spectrum of phenotypes that might 
be associated with SCN1A mutations. We also aimed to performing phenotype-genotype 
correlations of SCN1A mutations with specific epilepsy syndromes and possibly describe 
the clinical characteristics of fever-provoked seizures associated with SCN1A mutations.  
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Methods 
Patients recruitment 
We recruited subjects with either focal or generalized idiopathic epilepsies whose 
seizures were particularly increased during febrile episodes. Patients were collected from 
child neurologists and epileptologists around Italy and other European countries. Informed 
consent was obtained from parents or guardians.  
Clinical classification 
A detailed clinical history including pre and perinatal antecedents, seizures age of 
onset and semiology, occurrence of fever-provoked seizures, cognitive functions, EEG 
recordings and MRI were directly collected from the parents and/or other relatives for 
patients seen at the Epilepsy, Neurophysiology and Neurogenetic Unit of the Department of 
Child Neurology and Psychiatry of the Stella Maris Foundation, Pisa, Italy. For patients 
referred from other centres around Italy or Europe, medical records from child neurologists, 
paediatricians, hospitals and other treating doctors were collected and reviewed whenever 
possible. Genealogical information and family trees were also collected when available.  
Epileptic seizures and epilepsy syndrome diagnoses were performed according to 
the International League Against Epilepsy classifications (Engel, 2001; ILAE, 1981; ILAE, 
1989). Seizures lasting longer than 30 minutes were classified as status epilepticus, whereas 
seizures lasting at least several minutes but definitely less than 30 where considered as 
‘prolonged seizures’. Classical SMEI was diagnosed when all of the following features 
were present: onset in the first year with hemiclonic or generalized febrile or afebrile 
seizures, evolution of myoclonic seizures, atypical absences and partial seizures, and 
progressive cognitive impairment (Dravet, 2002). The term “borderline” severe myoclonic 
epilepsy of infancy (SMEB) was used for cases without a number of the key features of 
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SMEI (e.g. lack of generalized spike wave discharges, lack of myoclonus, limited number 
or atypical seizure types) (Dravet, 2002; Fukuma et al., 2004; Oguni et al., 2001). Patients 
with febrile seizures beyond age 6 years and/or with afebrile seizures in early or mid 
childhood were classified as febrile seizure plus (FS+) (Scheffer and Berkovic, 1997; Singh 
et al., 1999a).  
When classical FS, FS+ with or without other seizure types, occurred in families we 
considered them as part of the GEFS+ spectrum (Scheffer and Berkovic, 1997; Singh et al., 
1999a).  Myoclonic astatic epilepsy (MAE) was considered as sporadic if no other family 
members had had seizures or it was included in the GEFS+ spectrum when it presented in 
families (Scheffer and Berkovic, 1997; Singh et al., 1999a). Patients in whom despite 
clinical information a diagnosis could not be made were designated as ‘unclassified 
epilepsy’. 
Molecular analysis 
Peripheral blood samples were obtained from patients and from almost all of their 
parents, genomic DNA was extracted using standard protocol. The 26 coding exons of the 
SCN1A gene were amplified by PCR reaction with primers designed to amplify each exon 
and the flanking intron splice site. PCR products were then analyzed by denaturing high 
performance liquid chromatography (dHPLC) on a Wave automated instrument 
(Transgenomic Inc., Cheshire). Primers sequences and dHPLC condition are available upon 
request. Abnormal profiles observed on dHPLC screening were subsequently analyzed by 
direct sequencing. Sequencing analysis on both DNA strands was performed on a ABI3100 
avant sequencer (Applied Biosystems, CA, U.S.A.) using the BigDyes v1.1 terminator 
Cycle Sequencing Kit following the manufacturer's protocol. Sequences were analyzed 
using as reference for the Seqscape program (Applied Biosystems, CA, U.S.A.) the 
genomic region of the Genbank sequence NC_000002 encompassing the SCN1A gene. 
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Available parents’ DNA was checked for the mutation identified in their child by direct 
sequencing.  
Sequence changes were interpreted as mutations when they resulted in: a) truncating 
mutation (frameshift, stop or splice site mutation; b) missense mutations when the change 
lead to an amino-acid substitution that was not previously reported as polymorphism, was 
not present in 200 control alleles and/or it arose de novo. The coding synonymous and 
intron nucleotide changes were investigated in silico using the Neural Network Splice Site 
Prediction software (http://www.fruitfly.org/seq_tools/splice.html) in order to identify 
alteration in the mRNA splicing process. The mutations found were coded using the DNA 
mutation checker (http://www.ebi.ac.uk/cgi-bin/mutations/check.cgi) and the protein 
P35498 of the Swiss-Prot Database reference. 
Genotype-phenotype correlations  
Based on epilepsy syndrome diagnosis, the 132 patients were divided in: 1) SMEI, 
2) GEFS+, and 3) other phenotypes. A clinical analysis focussed on seizure types and age 
of seizures onset, with particular attention to seizures provoked by fever, was performed in 
the three groups. Based on previous studies of genotype-phenotype correlations of SMEI 
patients (Ceulemans et al., 2004; Fukuma et al., 2004; Ohmori et al., 2003) we further 
subdivided our SMEI probands in three groups according to the SCN1A analysis: a) 
truncating, b) missense and c) no mutations. ANOVA test was used for statistical analysis 
to evaluate differences of age of seizures onset between the three groups of SMEI patients. 
To evaluate the existence of hot spots regions, where mutations of SCN1A are more 
likely to be found, we compared the number of the identified mutations in each exon 
(including 10 nucleotides up and down stream the exon) to the number of expected 
mutations using Fisher’s exact test. We also performed a Fisher’s exact test to evaluate the 
location of SCN1A mutations grouping the exons according to their coding protein domain: 
SCN1A: phenotype-genotype correlations  9 
N-terminal + DI; Loop 1; DII; Loop 2; DIII; Loop 3 and DIV + C-term.  
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Results 
A total of 132 probands, 74 females and 59 males, with idiopathic epilepsies 
including febrile seizures (FS) were studied. Patients were collected from various European 
countries including: Italy (82), United Kingdom (24), Portugal (23), Spain (1), Denmark (1) 
and  Israel (1). The mean age at the time of the study was 9 years (median 6,5 ranging from 
1 to 38 years). Epilepsy phenotypes of the 132 probands are shown on Table 1. 
  
Epilepsy syndromes 
1. Severe myoclonic epilepsy of infancy (SMEI) 
We studied 55 patients (27 females and 28 males) with a clinical diagnosis of SMEI 
(39) and SMEB (16 patients). Mean age at the time of the study was 9,5 years (median 8,6 
± 5,1, ranging from 2,5 to 20,8). Patients were divided in 3 groups according the SCN1A 
mutational screening result: 1) truncating, 2) missense and 3) no mutations. Detailed 
clinical information of patients with truncating and missense mutations are presented on 
Table 2 and 3 respectively. 
a) Group 1: patients with SCN1A truncating mutations  
Truncating mutations were identified in 21 patients with SMEI (18) and SMEB (3) 
(see Table 2 and Figure 1a). All patients had recurrent FS and in the majority of patients FS 
were the first clinical expression occurring between the 4th to 5th months of life (mean 4,6 
months; median 4; ranging from 2 to 9). Status epilepticus, either febrile (14 patients; 
66%), afebrile (13 patients; 62%) or both (7 patients; 33%), was reported in all patients. 
Febrile status epilepticus had a mean age at onset of 9,6 months (median 7, ranging from 3 
to 40), afebrile status epilepticus had a mean age at onset of 12,5 months (median 9, 
ranging from 3 to 48). Afebrile tonic-clonic, tonic or hemiclonic seizures, often prolonged, 
occurred in 19 (90%) patients, mean age at onset was 13 months (median 10, ranging from 
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3 to 42).  Symmetric or asymmetric bilateral myoclonic seizures occurred in 14 (67%) 
patients and in the majority of them began during the second year of life (mean age of onset 
19 months; median 13; ranging from 4 to 38). Complex partial seizures were seen in 16 
(76%) patients with a mean age of onset at 23 months (median 18; ranging from 3 to 72). 
Atypical absences occurred in 13 (62%) patients with mean age of onset at 34 months 
(median 36; ranging from 10 to 72). All patients had cognitive impairment ranging from 
mild to severe. A family history for seizures including FS was present in 11 (52%) patients. 
The sister of a SMEI patient (see Table 2, mutation IVS4+1 G>A splicing) had a clinical 
history also consistent with SMEI with prolonged febrile seizures beginning around 6 
months of age and followed by the later appearance of myoclonic seizures. Their father had 
had FS from infancy to childhood. Detailed clinical information of each patient and further 
data regarding EEG, photosensitivity and therapy are reported on Table 2.  
b) Group 2: patients with SCN1A missense mutations 
Missense mutations were found in 16 patients, 8 males and 8 females with SMEI 
(11) and SMEB (5) (see Table 3 and Figure 1b). Recurrent, often prolonged, FS were seen 
in all patients with mean age at onset of 6,7 months (median 7; ranging from 3 to12). Status 
epileptics was present in 12 patients (75%) either febrile (9 patients; 56%), afebrile (8 
patients; 50%) or both (5 patients; 35.5%). Febrile status epilepticus had a mean age at 
onset of 11 months (median 10; ranging from 4 to 28); afebrile status had a similar mean 
age at onset (median 5; ranging from 4 to 42). All but one patient had afebrile tonic-clonic, 
tonic or hemiclonic seizures, often prolonged, beginning during the first year of life (mean 
age of onset 10 months; median 7,5; ranging from 3 to 30). Clusters of symmetric or 
asymmetric myoclonic seizures occurred in 11 (69%) patients, age at onset was known in 
10 of them, with a mean of 25 months (median 24; ranging from 7 to 60). Atypical absence 
seizures beginning around the third year of life (mean 38 months; median 40; ranging from 
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7 to 72) were seen in 7 (44%) of the 16 patients. Complex partial seizures were documented 
in 13 (81%) patients with a mean age at onset of 17 months (median 12; ranging from 3 to 
42). All patients had cognitive impairment ranging from mild to severe. A family history of 
seizures including FS, was present in 9 of the 16 patients (56%) and in two of them 
relatives with seizures were found in both paternal and maternal branches of the family. 
Detailed clinical information of each single patient and further data regarding EEG, 
photosensitivity and therapy are reported on Table 3. 
c) Group 3: patients without SCN1A mutations 
Molecular analysis did not reveal SCN1A mutations in 18 patients (7 females and 11 
males), 8 with SMEB and 10 with SMEI. FS beginning around age 10 months (median 8,5; 
ranging from 4 to 24 months) occurred in all patients. Status epileptics was documented in 
12 patients (67%) either febrile (10 patients; 55.5%), afebrile (7 patients; 39%) or both (5 
patients 28%). Febrile status epilepticus began around the age of 12 months in most 
patients with the exception of one in whom status appeared at the age of 7,5 years (median 
12; ranging from 4 months to 7,5 years). Afebrile status had a mean age at onset of 10 
months (median 9; ranging from 4,5 to 18). Afebrile seizures occurred in 13 (72%) patients 
with mean age of onset at 13 months (median 10; ranging from 2 to 14). Myoclonic 
seizures with mean age at onset of 26 months (median 22,5, ranging from 13 to 60) were 
present in 8 (44%) patients. Absence seizures were reported in 9 patients (50%), age of 
onset was known in 7 of them and had a mean of 24 months (median 24; ranging from 5 to 
51). Partial seizures occurred in 11 (61%) patients with mean age of onset of 26 months 
(median 24; ranging from 8 to 60). Borderline cognitive functions were seen in 5 patients 
the remaining had from mild to severe cognitive impairment. A family history of seizures 
including febrile seizures was present in 10 probands (55,5%). 
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2. Generalized epilepsy with febrile seizure plus (GEFS+) 
A diagnosis of generalized epilepsy with febrile seizures plus was made in 24 patients 
(13 females and 11 males) aged from 1 to 26 years (mean 8; median 6,5 years). Febrile 
seizures occurred in all patients and had a mean age at onset of 17 months (median 12, 
ranging from 5 to 60). Only two patients had, at 10 and 35 months respectively, a single 
episode of febrile and afebrile status epilepticus. Afebrile tonic-clonic seizures were seen in 
19 patients with mean age at onset of 43 months (mean 19; ranging from 3 to 108). Other 
seizure types included: myoclonic (seven patients), absences (two patients), myoclonic-
astatic (six patients) and partial seizures (nine patients).  
Of the 24 patients with GEFS+ spectrum three patients (12,5%) were found to 
harbour SCN1A mutations (see Figure 1b). Clinical details of the 3 patients are reported on 
Table 4. 
3. Other phenotypes 
Classical febrile seizures (see Table 1) were diagnosed in 10 patients, mean age of 
FS onset was 15 months (median 12,5; ranging from 8 to 31). All 10 patients had had not 
other seizure types. One patient had right HS on MRI and a mild deficit of the cognitive 
functions. A positive family history of epilepsy was detected in 9 probands and in one of 
them there was a bilinear occurrence of seizures. None of them had SCN1A mutations.  
Idiopathic generalized epilepsy of various subtypes (see Table 1) with antecedents 
of FS was documented in 14 patients and none of them carried SCN1A mutations. Three 
patients had sporadic myoclonic astatic epilepsy and SCN1A screening was also negative.  
The remaining 25 patients had various epilepsy phenotypes (see Table 1); the 
majority of them (18), despite the analysis of EEG and clinical information, could not be 
classified. As described in the methods (selection criteria), all patients had, either focal or 
generalized seizures, or both, which increased in frequency during febrile episodes. Mean 
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age of seizures onset was 20 months (median 17, ranging from neonatal period to 84 
months). None of them had SCN1A mutations.  
SCN1A molecular analysis  
dHPLC analysis of SCN1A in the 132 patients included in the study showed 64 
different abnormal chromatograms.  Direct sequencing revealed that 39 out of the 64 
dHPLC abnormal profiles corresponded to 40 mutations: 19 missense, 5 nonsense, 10 
frameshift, 4 splice site mutations and 2 silent nucleotide substitution that in silico seemed 
to modify the mRNA splicing process (see Figure 1a and b). Molecular analysis of the 34 
available parent’s showed that 28 mutations were de novo and 6 were inherited (2 
truncating and 4 missense mutations) (see Tables 2, 3 and 5). Of the 40 SCN1A mutations 
identified in our study, 33 had not been previously reported. The position of the missense 
mutations within the SCN1A protein is shown in the graphic (see Figure 2). The direct 
sequencing of the remaining 25 dHPLC abnormal chromatograms showed that they were 
polymorphisms (12 not been previously reported, data not shown).  
Genotype-phenotype correlations 
The analysis of the age of seizures onset between the three groups of SMEI patients 
with: a) SCN1A truncating mutations, b) SCN1A missense mutations and c) no SCN1A 
mutations showed that the differences of the age of FS onset was extremely significant 
between the three groups (p=0,0007, ANOVA test). Patients with truncating mutations had 
an earlier seizures onset, around the 5th month of age, patients with missense mutations had 
a later FS onset, around the 7th month and finally individuals without SCN1A mutations had 
an age of onset around the 10th month of life.  For the remaining seizure types − febrile and 
afebrile status afebrile tonic-clonic or hemiclonic, myoclonic, absence and partial seizures 
− there were not statistically significant differences in age of seizures onset amongst the 3 
groups of patients.   
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The statistical analysis comparing the number of the identified mutations in each 
exon to the number of expected mutations did not find statistically significant differences 
between exons (p>0,05) (Fisher’s exact test). The highest number of mutations (10 out 40) 
was found in exon 26. This data however, did not reach a statistically significant p-value 
because this is the biggest exon, therefore carrying a higher chance of being hit by a 
mutation. A similar analysis was performed grouping the exons according to their coding 
protein domain (N-terminal + DI; Loop 1; DII; Loop 2; DIII; Loop 3 and DIV + C-term) 
and similarly there were not statistically significant differences in the domains (p> 0,05). 
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Discussion 
Mutation rates 
In our cohort of 132 patients with idiopathic epilepsies with fever-provoked seizures 
in infancy and early childhood, classical SMEI was diagnosed in 39 (30%) and SMEB in 
16 (12%) patients. Mutations of SCN1A were identified in 29 classical SMEI (74%) and 8 
SMEB patients (22%). We obtained a prevalence of about 70% of SCN1A mutations in 
SMEI and SMEB patients, which is intermediate between the lowest percentage of 35% 
(Nabbout et al., 2003; Wallace et al., 2003) and the highest reported by the Belgium 
(100%) (Claes et al., 2001) and Japanese groups (78%) (Fujiwara et al., 2003; Ohmori et 
al., 2002; Sugawara et al., 2002). Ascertainment bias is likely to influence the proportion of 
patients carrying SCN1A mutations identified by the different authors. Although SMEI is a 
well-defined epilepsy syndrome clinicians are still debating whether myoclonic seizures are 
an essential feature of SMEI. Supported by the definition endorsed by the International 
League Against Epilepsy, in this study myoclonic seizures were not regarded as an 
essential diagnostic criteria for classical SMEI. We, instead, based our clinical 
classification predominantly on age of onset and on the occurrence of prolonged febrile 
hemiclonic or generalized seizures often evolving into status epilepticus. The results of 
SCN1A analysis supported our diagnostic criteria; the 29 SMEI patients carrying mutations 
manifested febrile seizures at onset, followed by febrile or afebrile seizures evolving into 
status epilepticus in most of them, whereas myoclonic seizures were noted only in 25 out of 
the 37 (67.5%) patients with mutations.  
Clinical criteria for SMEB are even less defined, therefore easily over-or 
underestimated. Due to these nosological issues the correlation of SMEB with SCN1A 
mutations in our patients decreased to 50%. Furthermore, in our study, the milder SMEB 
phenotype correlated with a higher proportion of missense (70%) rather than truncating 
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mutations (30%). Electroclinical and genetic molecular findings suggest that SMEI and 
SMEB are closely related, representing a spectrum of phenotypes that could be categorized 
under the term of Dravet’s syndrome. Clinical differences in some patients seem to be 
related to the type and location of SCN1A mutations whereas in other patients there might 
be some yet-undiscovered molecular genetic mechanisms. 
Is SMEI an inherited disorder?  
The majority of SCN1A mutations (89%) were de novo, whereas only 4 (11%) were 
inherited (2 truncating and 2 missense mutations). One of the two inherited truncating 
mutations was transmitted from a father who had a single seizure (Table 2, 
D1293delX1299 mutation). The second familial SCN1A truncating mutation (Table 2 
IVS4+1 G>A splicing) was found in the probands’ sister whose phenotype was also 
consistent with SMEI. The two siblings inherited the mutation from a mildly affected father 
with only FS from infancy to childhood. A literature review showed only one other family 
described in which SCN1A truncating mutation was inherited from a mildly affected mother 
(Nabbout et al., 2003). 
In our cohort of SMEI probands, similarly to previous studies (Nabbout et al., 2003; 
Wallace et al., 2003), 56% had close relatives with seizures including febrile seizures, 
favouring the hypothesis that SMEI might be an inherited disorder. This hypothesis is 
confirmed by several observations including the family here reported in which both sisters 
had SMEI and SCN1A mutation, as well as the reports of additional families in which at 
least two affected members had SMEI, (Fujiwara et al., 1990; Gennaro et al., 2003; Kimura 
et al., 2005; Singh et al., 2001) including two families with SCN1A missense and truncating 
mutations (Gennaro et al., 2003; Kimura et al., 2005). High rates of family history of 
epilepsy and familial occurrence of SMEI are however, hard to reconcile with the finding 
that the majority of SCN1A mutations in SMEI patients are de novo.  
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Genotype−phenotype correlations 
We observed a mild predominance of truncating (52,5%) over missense (47,5%) 
mutations. Patients with SMEB (8) where more likely to have missense (5/16; 31%) than 
truncating mutations (3/21; 14%), whereas patients with classical SMEI (29) had both 
truncating (18/21, 86%) and missense mutations (11/16, 69%).  
Similarly to previous studies, we found that missense mutations in the pore forming 
parts S5-S6 of the channel occurred in 10 out of the 16 SMEI/SMEB patients (62,5%) and 
only in one of the three GEFS+ patients (see Figure 2). Mutations in the pore forming 
region seem to correlate in 70% with the classical SMEI type and only with 30% of the 
SMEB phenotype. Unlike previous studies, we did not find missense mutations in the 
voltage sensor part S4. The remaining six patients with SMEI/SMEB and two with GEFS+ 
carried missense mutations outside the important pore S4-S6 region (see Figure 2).  
Statistical analysis of the mean age of onset of FS showed that patients with 
truncating mutations have the earliest onset followed by patients with missense mutations 
having an intermediate onset and individuals without SCN1A mutations showing the latest 
age of onset around the 10th month of life. The difference between the three groups was 
statistically very significant (p=0,0007).  
Several recurrent mutations are emerging as the number of published studies 
increases (Mulley et al., 2005). In our patients only six of the 39 mutations identified, had 
been previously described (see Tables 2 and 3). In four unrelated SMEI patients we found a 
truncating mutation (IVS4+1  G>A, Table 2 and Figure 1a) recurring twice and two 
missense mutations affecting the same aminoacid (Arg393Cys and Arg393His, see Table 3 
and Figure 1b).  
The SCN1A mutations so far identified seem to be scattered across SCN1A protein 
with some clustering occurring in the C-terminus, to some extent in the N-terminus and in 
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the loops between the segments 5 and 6 of the first three domains (Mulley et al., 2005). The 
statistical analysis (Fisher’s exact test) of the position of the mutations did not uncover hot 
spot regions in our patients. The highest number of mutations (10 out 40) was found in 
exon 26. This data however, did not reach a statistically significant p-value because this is 
the biggest exon, therefore carrying a higher chance of being hit by a mutation.  
GEFS+ and SCN1A mutations  
Amongst GEFS+ phenotypes the rate of SCN1A mutations was around 12%. The 
W1204R mutation identified in a child with FS+ and his father had previously been 
reported in a GEFS+ family (Escayg et al., 2001). The proband of this small GEFS+ family 
had a left hippocampal sclerosis (HS) on MRI scan. Spampanato et al. (2003) performed 
some functional studies of the W1204R mutation and showed it to cause an alteration of the 
voltage-dependent channel gating that could result in neuronal hyperexcitability 
(Spampanato et al., 2003). The remaining two SCN1A mutations have not previously been 
reported.  
We identified two aminoacid substitutions: Arg604His and Ala1161Thr in a patient 
with myoclonic astatic epilepsy within a GEFS+ family. The same substitutions were 
previously described in three patients with JME (Escayg et al., 2001). These changes did 
not co segregate with seizure disorder in the JME families but were not identified in 
controls either (Escayg et al., 2001). In our patient the two changes, although not identified 
in 200 control alleles, were both inherited from the unaffected father thus suggesting that 
they are most likely to be rare polymorphisms. 
How much genetic overlapping is there between SMEI and GEFS+? 
The clinical similarities between SMEI and GEFS+, including the frequent 
occurrence of febrile seizures, the family history and the shared molecular genetic 
aetiology, have prompted the hypothesis that these disorders represent two extremes in 
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clinical presentation of the same condition (Claes et al., 2003; Singh et al., 2001). 
Molecular evidences of a shared aetiology include the finding that a mutation in the same 
aminoacid can give rise to both conditions: the mutation R1648C caused GEFS+ in a 
family (Escayg et al., 2000) whereas the mutation R1648H caused SMEI in another patient 
(Ohmori et al., 2002). More than one hundred SCN1A mutations have been defined to date 
and a mutational diversity between SMEI and GEFS+ has been observed. SCN1A 
truncating mutations occur only in SMEI patients whereas missense mutations are found in 
both SMEI and GEFS+. Furthermore, missense mutations causing SMEI are predominantly 
found in the pore-forming region of SCN1A whereas mutations associated with GEFS+ are 
spread throughout the gene. A SMEI patient within a GEFS+ family carrying a mutation of 
the GABAA receptor γ2 subunit gene is also on record (Harkin et al., 2002).  
SCN1A and MRI abnormalities 
Usually, neuroimaging studies in SMEI do not demonstrate brain lesions (Dravet, 
2002; Nabbout et al., 2003) but studies designed to evaluate MRI abnormalities with 
special attention on the temporomesial structures, have not been performed. Only a 
retrospective study is on record, reporting that 10 of the 14 patients with SMEI had HS 
although none of the patients had temporal lobe epilepsy (Siegler et al., 2005). None of the 
14 patients was tested for SCN1A mutations.  
In our cohort of patients we identified three patients with SCN1A mutations and 
clearcut focal MRI brain abnormalities. In these patients MRI abnormalities did not seem to 
be an epiphenomenon but they contributed to the patient’s epileptogenesis. The MRI study 
of one patient with SMEB and with complex partial seizures arising from the right temporal 
region, showed high signal intensity in the right temporal lobe with hippocampus volume 
reduction (Table 2, Figure 3A). The second patient with FS+ and focal seizures showed left 
HS on MRI (Table 3, patient 1 and Figure 3B) and the third patient with FS+ had left 
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temporal lobe hypoplasia on MRI (Table 3, patient 2). The true incidence of focal MRI 
brain abnormalities in SMEI patients needs to be further studied with properly designed 
studies. However, the apparently low rate of structural abnormalities raises the possibility 
that the occurrence of congenital or secondary MRI abnormalities requires further factors, 
either genetic or aquired, in addition to SCN1A mutations and prolonged FS.  
Phenotypes other than SMEI and GEFS+ 
None of the patients with idiopathic epilepsies with fever-provoked seizures besides 
SMEI and GEFS+ carried mutations in the SCN1A gene. Recently, a large Italian family 
with simple FS cosegregating in affected family members was reported to carry a SCN1A 
missense mutation (Mantegazza et al., 2005). We did not identify SCN1A mutations in the 
10 patients with simple FS and with a family history of FS (data not shown) included in this 
study, suggesting that SCN1A causes familial simple FS only in rare families.   
 
In conclusion, SCN1A is the most relevant epilepsy gene with the largest number of 
epilepsy-related mutations so far identified. The high correlation between SMEI and 
SCN1A mutations suggests a phenotypical specificity of SCN1A rather than a dysfunction 
of neurons exacerbated by high body temperature. What causes SMEI when there is no 
detectable SCN1A mutation remains to be identified.  
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Table 1: epilepsy phenotypes of the 132 patients screened for SCN1A  
 
Syndromic phenotypes No of patients  SCN1A mutations  
1) Severe myoclonic epilepsy of infancy   
(SMEI / SMEB) 
 
55 37 (67%) 
 
2) GEFS+ spectrum  
 
25 3 (12%) 
3) Other phenotypes 
Sporadic MAE 
 
3 
 
0 
FS 10 0 
CAE 
CAE>JME 
JAE  
JME 
IGE-TCS 
7 
2 
2 
1 
2 
0 
0 
0 
0 
0 
Uncl epilepsy with fever-sensitive sz 
Infantile convulsions 
Atypical BRE 
Idiopathic fever-sensitive focal epilepsy 
18 
2 
1 
3 
0 
0 
0 
0 
 
Total  
 
132 
 
40 (30%) 
 
BRE= benign rolandic epilepsy; CAE= childhood absence epilepsy; FS= febrile seizures; 
IGE-TCS= idiopathic generalized epilepsy with tonic-clonic seizures; GEFS+= generalized 
epilepsy with febrile seizures plus; JME= juvenile myoclonic epilepsy; JAE= juvenile 
absence epilepsy; MAE= myoclonic astatic epilepsy; SMEB= borderline severe myoclonic 
epilepsy of infancy; sz= seizures; Uncl= unclassified
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Table 2: clinical information of the 21 SMEI/SMEB patients with SCN1A truncating mutations 
 
Gender Age 
(yrs) 
FS onset* FS status 
onset* 
Afeb status 
onset* 
Afeb sz 
onset* 
Myo sz 
onset* 
Abs sz 
onset* 
Partial sz 
onset* 
EEG IPS  AEDs Efficacy  Family 
history 
Syndrome 
Phenotype 
SCN1A screening                           
M 10.5 3 3 3 _ Unk Unk 3 GSW Y VPA+ TPM 
+CLB+STP 
Partial sz 
reduction 
 N SMEI c.1702 C>T  
Arg568X (Ohmori et al., 
2002) 
Parents not 
available 
F 3.2 9 14 _ 12 12 24 14  multiF SW  N VPA+ PB+CLB N  Y SMEI c.570 G>A  
Trp190X 
De novo 
F 12,4 3 _ 9 7 12 _ _ bifrontal SW N VPA+ TPM Partial sz 
reduction 
 Y SMEB c.1857_1858insGCAAC 
S620ins624X 
De novo 
F 17,7 5 _ _ 11 20 36 37 GSW & 
multiF 
N VPA+TPM+LT
G+CZP 
N  Y SMEI IVS1 -3  C>A De novo 
F 14 3 _ 24 10 38 36 12 GSW N  VPA+STP Partial sz 
reduction 
 N SMEI  c.249 C>G  
Tyr83X (Nabbout et al., 
2003) 
De novo 
F 9.5 6 40 _ 18 30 42 38 GSW & 
multiF 
Y VPA+TPM Partial sz 
reduction 
 bilineal  SMEI c.2586 A>G Arg862Arg 
De novo 
F 16.3 4 4 Uncertain 5 Yes Yes _ GSW Y VPA+TPM Y  N SMEI c.731_732delGT  
V244delX275 De novo 
M 6.2 3 9 _ 20 7 _ 20 Right T S Y VPA 
+TPM+CLB 
Partial sz 
reduction 
 N SMEI IVS16 -1 G>A acceptor 
splice site De novo 
F 6.4 5 _ 12 12 14,5 24 12 GSW & Focal Y VPA 
+TPM+CZP 
Partial sz 
reduction 
 N SMEI 
c.1624 C>T  Arg542X De novo 
F 4.8 3 _ 11 3 12 _ 3 MultiF SW Y VPA+ TPM+ 
CZP 
Y  N SMEI c.2608_2614delGCAAAAT  
A870delX874 De novo 
M 6 2 _ 48 36 36 72 72 GSW Y VPA+ TPM+ 
CZP 
Partial sz 
reduction 
 N SMEI c.5367_5368delCA 
F1789delX1793 
Parents not 
available 
M 8 3 13 13,5 6 10 10 6 GSW Y VPA + PB+ ETS 
+ GVG 
N  Y SMEI c.3347delC  
P1116delX1119 De novo 
M 12.1 9 9 _ 9 24 48 48 Unkown Y VPA+TPM+CL
B+STP 
Partial sz 
reduction 
 Y SMEI c.3878delA 
D1293delX1299 Familial 
M 4.8 6 6 6 4 _ _ 6 T SW > R N VPA+CZP+CL
B + STP 
Partial sz 
reduction 
 N SMEB IVS4+1  
G>A splicing (Fujiwara et 
al., 2003) 
De novo 
F 17 2.5 3 _ 4 _ 36 unk MultiF SW Y VPA+PB+ CLN N  Y SMEI c.3276insAT 
I1242ins1270X 
De novo 
M 14,4 4 5 8 6 32 30 24 Focal SW N CBZ+TPM Partial sz 
reduction 
 Y SMEI c.5620delCGGGTTCT 
R1874delX1941 
De novo 
SCN1A: phenotype-genotype correlations  27 
M 8,8 5 6 6 4 4 24 24 GSW N TPM+Acetaz Partial sz 
reduction 
 Y SMEI c.5295delTTTT  
F1765delX1777 
De novo 
F 7 6 _ 6 _ Y Y _ Slow backgr N VPA+ 
TPM+STP 
Partial sz 
reduction 
 Y SMEI IVS4+1  
G>A splicing (Fujiwara et 
al., 2003) 
Familial 
F 5 7 7 _ 42 _ _ - GSW N PB+VPA+ 
TPM+CLP 
N  N SMEB c.4933 C>T   Arg1645X Parents not 
available 
M 17,5 3 3 10 24 12 24 36 GSW & 
multiF SW 
Y VPA+TPM + 
CZP 
N  Y SMEI c.4589insA      
K1517ins1536X  
De novo 
F 4,1 7 8 6 16 _ 36 16 GSW Y VPA+CLB+STP Partial sz 
reduction 
 N SMEI c.2415 G>A Leu805Leu  de novo 
Legend:  
Abs= absence seizures; Acetaz= acetazolamide;  Backgr= background; CLB= clobazam; CLN= clonazepam; F= female; FS= febrile convulsions; GWS= generalized spike-wave; IPS: Photosensitivity; M= male; MR= mental retardation; 
Myo= myoclonic seizures; MultiF= multifocal; N= negative; PB= phenobarbital; R= right; S= spikes; SMEB= severe myoclonic epilepsy of infancy borderline; SMEI= severe myoclonic epilepsy of infancy; SW= spike-waves; T= temporal;  
TPM= topiramate, STP= stiripentol;  VPA= valproic acid; Y= Yes;    absent; * age of seizures onset in months 
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Table 3: clinical information of the 16 SMEI/SMEB patients with SCN1A missense mutations 
 
Gender Age 
(yrs) 
FS                                              
onset* 
FS status              
onset* 
Afeb status                                      
onset* 
Afeb Sz       
onset* 
Myo sz                      
onset* 
Abs sz               
onset* 
Partial sz      
onset* 
EEG IPS AEDs Efficacy Family 
history 
Syndrome 
Phenotype 
SCN1A screening                           
F 15 7 10 13 9 36 48 9 GSW & 
multiF 
N VPA+LTG+CL
B 
N Y SMEI c.4888 G>A 
Val1630Met  
Familial  
M 5.7 10 _ _ 10 24 24 24 GSW & 
multiF 
N Unk Unk Y SMEI c.4822 G>T 
Asp1608Tyr  
De novo 
M 8.6 10 _ 42 30 Unk Unk 36 GSW & 
multiF 
N VPA+TPM+PB N Y SMEI c.5359 
Glu1787Lys  
Parents not available 
M 9.4 7 7 _ 24 40 40 40 GSW N VPA+CBZ+CL
B 
N Bilineal  SMEI c.2870 G>T  
Trp957Leu 
Parents not available 
M 5.6 7 _ 5 4,5 _ _ 42 GSW Y VPA + TPM + 
CLN 
Partial sz 
reduction 
Bilineal  SMEB c302G>A 
Arg101Gln 
(Fukuma et al., 
2004) 
De novo 
F 6.1 4 4 4 _ _ 48 24 GSW N LTG+TMP+CL
B+STP 
N Y SMEI c.4762 T>C 
Cys1588Arg 
De novo 
F 4.6 10 12 _ 8 _ _ _ MultiF N TPM+PB Partial sz 
reduction 
Y SMEB c.1066 A>G 
Arg356Gly 
Familial  
F 3,9 4 _ 4 4 _ _ 14 GSW N TPM+PB Partial sz 
reduction 
N SMEB c.4973 C>G 
Thr1658Arg 
Parents not available 
M 20.8 4 4 5 5 _ _ _ GSW N Unk Unk N SMEB c.1072 C>A 
Pro358Thr 
Parents not available 
F 10.7 3 14 12 11 24 _ Unk GSW & 
multiF 
Y VPA+ CLN + 
acetaloz 
N Y SMEI c.4408 G>T 
Gly1470Trp De novo 
F 9.7 3 _ _ 3 7 7 3 multiF Y VPA+ TPM + 
CLN 
N N SMEI c.4240 A>T  
Asn1414Tyr De novo 
F 8.6 3 _ _ 20 _ _ 3 GSW N VPA+TPM Unk Y SMEB c.5146 T>C 
Cys1716Arg De novo 
F 11.9 4 28 _ 5 60 28 5 GSW & 
multiF 
N VPA + CLN + 
CLB 
N N SMEI c.1178 G>A 
Arg393His (Claes 
et al., 2003) 
De novo 
M            4,8 12 _ _ 14 20 _ 12 GSW & 
multiF 
 LTG+CLB N N SMEI c.965 G>T 
Arg322Ile 
Parents not available 
M 13,1 12 12 _ 7 7 72 7 GSW & 
MultiF 
Y PB+CZP+ CBZ N N SMEI c.1177 C>T 
Arg393Cys 
De novo 
M 4,7 8 8 4 4 12 _ 4 GSW & 
Focal 
N PB+VPA N N SMEI c.5348 C>T 
Ala1783Val 
De novo 
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Legend:  
Abs= absence seizures; Acetaz= acetazolamide;  Afeb= afebrile;  Backgr= background; CBZ= carbamazepine;  CLB= clobazam; CLN= clonazepam; F= female; FS= febrile convulsions; GWS= generalized spike-wave;  IPS: 
Photosensitivity;  LTG= lamotrigine;  M= male;  MR= mental retardation;  Myo= myoclonic seizures;  MultiF= multifocal; N= negative; PB= phenobarbital; TPM= topiramate; S= spikes;  SMEB= severe myoclonic epilepsy of infancy 
borderline;  SMEI= severe myoclonic epilepsy of infancy;  Sz= seizures;, STP= stiripentol;  Unk: unkown; VPA= valproic acid; Y= Yes;   Yrs= years    absent; * age of seizures onset in months. 
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Table 4: clinical details of 3 patients with GEFS+ and SCN1A mutations 
 
 Gender Age (y) FS onset* Afeb sz                     
onset* 
Myo sz                  
onset* 
Abs onset* Partial sz 
onset* 
EEG AEDs Cognitive Family Syndrome 
Phenotype 
MRI SCN1A screening 
1 M 4.9 8 40 _ _ 48 L T slowing TPM Language 
delay 
Y FS+ L HS  c3610 T>C 
Trp1204Arg 
(Escayg et al., 
2000) 
Familial 
2 M 2,2 6 7 _ _ _ N VPA N Neg FS+ L T 
hypoplasia 
c.220 T>C 
Ser74Pro 
De novo 
3 M 14 24 108 36 36 8 GSW LEV +VPA mild MR Y MAE/GEFS+ N c.5060 T>C                  
Phe1687Ser  
Familial 
 
Legend 
Abs= absences; AEDs= antiepileptic drugs; Afeb= afebrile; FS= ferbile seizures; GSW= generalized spike-waves; HS= hippocampal sclerosis; L= left; LEV= levetiracetam; M=male; Myocl= myoclonic; MR= 
mental retardation; N= normal; Neg= negative; T= temporal; TPM= topiramate; VPA= valproic acid; *= months; Y=yes; y=years               
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Figures legend 
Figure 1 
a) Graphic representation of the SCN1A protein showing the location of the truncating 
mutations. In the upper part of the figure are reported mutations leading to truncated SCN1A 
protein and to mRNA splicing alteration (underlined) associated with classical severe 
myoclonic epilepsy of infancy; in the lower part are reported the truncating mutations 
associated with borderline severe myoclonic epilepsy of infancy (SMEB).  
b) Graphic representation of the SCN1A protein showing the location of the missense 
mutations. In the upper part of the figure are reported missense mutations associated with 
classical severe myoclonic epilepsy of infancy (SMEI); in the lower part are reported the 
missense mutations associated with borderline severe myoclonic epilepsy of infancy 
(SMEB) and with generalized epilepsy with febrile seizures plus (GEFS+).  
Figure 2 
Graphic representation showing the location of the missense mutation according to the  
protein domains: N or C terminal; pore region; insulating region; voltage sensor; 
interdomain and other regions. Within the protein domains mutations have also been 
subdivided according to the phenotype: white for GEFS+, grey for SMEB and black for 
SMEI  
Figure 3 
A) Brain MRI scan of a patient with SMEI and SCN1A truncating mutation showing high 
signal intensity in the right temporal lobe with hippocampus volume reduction (arrows).  
B) Brain MRI scan of a patient with GEFS+ spectrum and SCN1A missense mutation 
showing left hippocampal sclerosis (arrows)  
 
